Balachandran Palat, Agarwal Shaleen, Krishnani Narendra, Pandey Chandra M, Kumar Ashok, Sikora Sadiq S, Saxena Rajan, Kapoor Vinay K
Department of Surgical Gastroenterology, Sanjay Gandhi Post-Graduate Institute of Medical Sciences, Lucknow, India.
J Gastrointest Surg. 2006 Jun;10(6):848-54. doi: 10.1016/j.gassur.2005.12.002.
The aim of this study was to examine the predictors of long-term survival (> 24 months) in patients with gall bladder cancer. A retrospective review of 117 cases of gall bladder cancer resected between 1989 and 2000. The resections included 80 simple cholecystectomies and 37 extended procedures. Patients with survival > 24 months (n = 44) were compared with those having survival < 24 months (n = 73) for 17 prognostic factors. Overall median survival was 16 months with a 5-year survival of 27%. T status (P = .000) and adjuvant chemoradiotherapy (P = .001) were independent predictors of long-term survival. Survival advantage was seen in T3N+ve disease (P = .007) with extended procedures. Complete (R0) resection was attained in 30 patients with a 5-year survival advantage of 30% as compared with incomplete (R1) resection (P = .0002). Adjuvant chemoradiotherapy improved survival in simple cholecystectomy group (P = .0008) but no advantage was seen after extended procedures. Stage III (P = .001) and node-positive disease (P = .0005) had significant benefit with adjuvant therapy. Poor differentiation and vascular invasion were associated with poor long-term survival. R0 resection was associated with prolonged survival. Extended procedures improved survival in patients with T3N+ve disease. Addition of chemoradiotherapy made significant improvement in long-term survival in stage III and node-positive lesions and in patients undergoing simple cholecystectomy. R0 resection predicted long-term survival in gall bladder cancer. T3 N+ve disease had better survival after extended procedures. Adjuvant chemoradiotherapy improved survival in stage III and node-positive disease. Poor differentiation and vascular invasion were adverse predictors of survival.
本研究的目的是探讨胆囊癌患者长期生存(>24个月)的预测因素。对1989年至2000年间切除的117例胆囊癌病例进行回顾性分析。手术包括80例单纯胆囊切除术和37例扩大手术。将生存>24个月的患者(n = 44)与生存<24个月的患者(n = 73)就17个预后因素进行比较。总体中位生存期为16个月,5年生存率为27%。T分期(P = .000)和辅助放化疗(P = .001)是长期生存的独立预测因素。在T3N阳性疾病患者中,扩大手术有生存优势(P = .007)。30例患者实现了根治性(R0)切除,与不完全(R1)切除相比,5年生存优势为30%(P = .0002)。辅助放化疗改善了单纯胆囊切除术组的生存率(P = .0008),但扩大手术后未显示出优势。Ⅲ期(P = .001)和淋巴结阳性疾病(P = .0005)接受辅助治疗有显著益处。低分化和血管侵犯与长期生存不良相关。R零切除与生存期延长相关。扩大手术改善了T3N阳性疾病患者的生存率。放化疗的加入显著改善了Ⅲ期和淋巴结阳性病变患者以及接受单纯胆囊切除术患者的长期生存率。R零切除可预测胆囊癌的长期生存。T3N阳性疾病在扩大手术后生存率更高。辅助放化疗改善了Ⅲ期和淋巴结阳性疾病的生存率。低分化和血管侵犯是生存的不良预测因素。